<DOC>
	<DOCNO>NCT00582738</DOCNO>
	<brief_summary>This study ass efficacy everolimus inhibitor fibrosis progression liver transplant patient recurrence hepatitis C viral infection transplant</brief_summary>
	<brief_title>Efficacy Everolimus Inhibitor Fibrosis Progression Liver Transplant Patients With Recurrence Hepatitis C Viral Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female patient 18 65 year age Recipients decease live donor Patients undergone primary liver transplantation least 6 month enrolment Recurrent Hepatitis C viral infection histologically confirm liver fibrosis ( stage IIV IshakKnodell scale ) obtain baseline within previous 6 month date enrolment Patients receive tacrolimus cyclosporine microemulsion without Mycophenolic acid ( MPA ) , without steroid . Absence acute rejection episode within previous 6 month date enrolment Patient allograft biopsy contraindicate Patient willing capable give write informed consent study participation able participate study 24 month Patients Hepatocellular carcinoma ( HCC ) within University California , San Francisco ( UCSF ) Criteria recurrence least 18 month OLT . Recipients multiple organ transplant patient undergone retransplantation Current biliary complication History drug alcohol abuse within 1 year enrolment Patients treat antihepatitis C virus treatment time enrollment within previous month date enrolment Coinfection Hepatitis B virus ( HBV ) Human Immunodeficiency Virus ( HIV ) Patients Leukocyte count ( WBC ) &lt; 3000/mm3 , platelet count &lt; 75000/mm3 Hemoglobin ( Hb ) &lt; 8 g/dl Patients proteinuria &gt; 1g/24 hour Patient current severe systemic infection Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Fibrosis progression</keyword>
	<keyword>recurrent hepatitis C</keyword>
	<keyword>viral infection</keyword>
	<keyword>liver transplant recipient</keyword>
	<keyword>everolimus</keyword>
	<keyword>Hepatitis C recurrence orthotopic liver transplantation ( OLT )</keyword>
</DOC>